Policy & Regulation
Hoth Therapeutics signs manufacturing agreement with Altasciences for HT-TBI therapy for secondary brain injury
20 September 2022 -

Biopharmaceutical company Hoth Therapeutics Inc (NASDAQ: HOTH) announced on Tuesday that it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.

The company said that HT-TBI is being developed as a novel, point-of-care therapy for the treatment and/or prevention of secondary brain injury resulting from ischemic stroke and traumatic brain injury (TBI).

Hoth Therapeutics added that HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals and military personnel.

HT-TBI formulation development and manufacturing work by Altasciences will be used to support a future Investigational New Drug (IND) Application to initiate clinical trials, Hoth Therapeutics also stated.